Cellebrite Names New CEO Amid Mixed Q2 Results and Lowered Full-Year Outlook
Event summary
- Shiven Ramji succeeds Thomas E. Hogan as CEO of Cellebrite, effective immediately.
- Cellebrite reports Q2 2026 ARR of $507.8M, up 21% YoY but below expectations.
- Company lowers FY26 ARR and revenue outlook due to longer sales cycles and slower Inseyets conversions.
- Adjusted EBITDA target raised despite revenue outlook reduction.
- Cellebrite secures first significant FedRAMP deal for Guardian, its SaaS-based evidence management solution.
The big picture
Cellebrite's leadership transition and mixed financial results reflect broader challenges in the digital investigation space, where AI-driven solutions face longer sales cycles and heightened regulatory scrutiny. The company's ability to pivot under new leadership will be critical as it competes with larger players in law enforcement and intelligence markets.
What we're watching
- Product Adoption
- How the adoption of newer products like Cellebrite Genesis and Guardian will impact near-term revenue growth.
- Sales Execution
- Whether Cellebrite can improve execution to meet revised full-year targets amid elongated sales cycles.
- Government Contracts
- The pace at which Cellebrite can secure additional FedRAMP-authorized deals to bolster its government cloud offerings.
Related topics